Schizophrenia Research
Volume 86, Issue 1 , Pages 15-22 , September 2006

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline

  • Henry A. Nasrallah

      Affiliations

    • University of Cincinnati, 231 Albert Sabin Way, PO Box 670559, Cincinnati, OH 45267-0559, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 513 558 4615.
    • ,
  • Jonathan M. Meyer

      Affiliations

    • VA San Diego Healthcare System, Department of Psychiatry, University of California, San Diego, 3350 La Jolla Village Drive, San Diego, CA 92161, United States
    • ,
  • Donald C. Goff

      Affiliations

    • Department of Psychiatry, Harvard University, Freedom Trail Clinic - Lindemann Mental Health Center, 25 Staniford St., Boston, MA 02114, United States
    • ,
  • Joseph P. McEvoy

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, United States
    • ,
  • Sonia M. Davis

      Affiliations

    • Quintiles Inc., 5927 South Miami Blvd, Morrisville, NC 27560, United States
    • ,
  • T. Scott Stroup

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Campus Box 7160, Chapel Hill, NC 27599-7160, United States
    • ,
  • Jeffrey A. Lieberman

      Affiliations

    • Department of Psychiatry, Columbia University, Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, United States

Received 26 April 2006 ,Revised 13 June 2006 ,Accepted 18 June 2006.

References 

  1. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of “statin” lipid-lowering drugs compared with guidelines. Archives of Internal Medicine. 2001;161:53–58(see comment)
  2. Allebeck P. Schizophrenia: a life-shortening disease. Schizophrenia Bulletin. 1989;15:81–89
  3. American Diabetes Association , American Psychiatric Association , American Association of Clinical Endocrinologists , North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry. 2004;65:267–272
  4. Bosworth HB, Calhoun PS, Stechuchak KM, Butterfield MI. Use of psychiatric and medical health care by veterans with severe mental illness. Psychiatric Services. 2004;55:708–710
  5. Brown S. Excess mortality of schizophrenia A meta-analysis. British Journal of Psychiatry. 1997;171:502–508
  6. Buckley PF, Miller DD, Singer BE, Arena J, Stirewalt EM. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research. 2005;79:281–288
  7. Bushe C, Holt R. Prevalence of diabetes and glucose intolerance in patients with schizophrenia. British Journal of Psychiatry. 2004;184:67–71
  8. Casey DE, Hansen TE. Excessive mortality and morbidity associated with schizophrenia. In:  Meyer JM,  Nasrallah HA editor. Medical Illness and Schizophrenia. Washington, D.C.: American Psychiatric Press, Inc.; 2003;p. 13–34
  9. Centers for Disease Control and Prevention . Prevalence of diabetes and impaired fasting glucose in adults—United States, 1999–2000. Morbidity and Mortality Weekly Report. 2003;52:833–837
  10. Citrome LL, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being?. Journal of Psychopharmacology. 2005;19:102–109
  11. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Canadian Journal of Psychiatry — Revue Canadienne de Psychiatrie. 2004;49:753–760
  12. Cradock-O'Leary J, Young AS, Yano EM, Wang M, Lee ML. Use of general medical services by VA patients with psychiatric disorders. Psychiatric Services. 2002;53:874–878
  13. Curkendall SM, Mo J, Glasser DB, Stang MR, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. Journal of Clinical Psychiatry. 2004;65:715–720
  14. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Australian and New Zealand Journal of Psychiatry. 2001;35:196–202
  15. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics. 2004;22:907–928
  16. Desai MM, Rosenheck RA, Druss BG, Perlin JB. Mental disorders and quality of diabetes care in the Veterans Health Administration. American Journal of Psychiatry. 2002;159:1584–1590
  17. Desai MM, Rosenheck RA, Druss BG, Perlin JB. Receipt of nutrition and exercise counseling among medical outpatients with psychiatric and substance use disorders. Journal of General Internal Medicine. 2002;17:556–560
  18. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. Journal of Nervous and Mental Disease. 1999;187:496–502
  19. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin. 2000;26:903–912
  20. Dixon LB, Kreyenbuhl JA, Dickerson FB, Donner TW, Brown CH, Wohlheiter K, et al. A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatric Services. 2004;55:892–900
  21. Druss BG. The mental health/primary care interface in the United States: history, structure, and context. General Hospital Psychiatry. 2002;24:197–202(see comment)
  22. Druss BG, Rosenheck RA. Use of medical services by veterans with mental disorders. Psychosomatics. 1997;38:451–458
  23. Druss BG, Rosenheck RA. Mental disorders and access to medical care in the United States. American Journal of Psychiatry. 1998;155:1775–1777
  24. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA. 2000;283:506–511(see comments)
  25. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM. Quality of medical care and excess mortality in older patients with mental disorders. Archives of General Psychiatry. 2001;58:565–572
  26. Durrington P. The human and economic costs of undertreatment with statins. International Journal of Clinical Practice. 2002;56:357–368
  27. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. Journal of Nervous and Mental Disease. 2004;192:19–27
  28. Goff DC, Sullivan L, McEvoy JP, Meyer JM, Nashrallah HA, Daumit G, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research. 2005;80:45–53
  29. Gotto AM. Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). American Journal of Medicine. 1999;107:36S–39S
  30. Grant T, Soriano Y, Marantz PR, Nelson I, Williams E, Ramirez D, et al. Community-based screening for cardiovascular disease and diabetes using HbA1c. American Journal of Preventive Medicine. 2004;26:271–275
  31. Gupta K, Gupta S. Undertreatment of hypertension: a dozen reasons. Archives of Internal Medicine. 2002;162:2246–2247([comment] author reply 2247–8)
  32. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. American Heart Journal. 2005;150:1115–1121
  33. Jin H, Meyer JM, Jeste DV. A typical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research. 2004;71:195–212
  34. Jones DR, Macia C, Barreira PJ, Fisher WH, Hargreaves WA, Harding CM. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatric Services. 2004;55:1250–1257
  35. Jorgensen P, Mortensen PB. Reactive psychosis and mortality. Acta Psychiatrica Scandinavica. 1990;81:277–279
  36. Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. Journal of Clinical Psychiatry. 2004;65:702–706
  37. Levinson Miller C, Druss BG, Dombrowski EA, Rosenheck RA. Barriers to primary medical care among patients at a community mental health center. Psychiatric Services. 2003;54:1158–1160
  38. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005;353:1209–1223
  39. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry. 2004;161:1334–1349
  40. McEvoy JP, Meyer JM, Nasrallah HA, Goff DC, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophrenia Research. 2005;80:19–32
  41. Meyer JM. Cardiovascular illness and hyperlipidemia in patients with schizophrenia. In:  Meyer JM,  Nasrallah H editor. Medical Illness and Schizophrenia. Washington, D.C.: American Psychiatric Press, Inc.; 2003;p. 59–89
  42. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research. 2004;70:1–17
  43. In:  Meyer JM,  Nasrallah HA editor. Medical Illness and Schizophrenia. Washington, D.C.: American Psychiatric Press, Inc.; 2003;
  44. Mortensen PB, Juel K. Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatrica Scandinavica. 1990;81:372–377
  45. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. British Journal of Psychiatry. 1993;163:183–189
  46. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. Journal of Clinical Psychopharmacology. 2004;24:S1–S6
  47. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Canadian Journal of Psychiatry — Revue Canadienne de Psychiatrie. 1991;36:239–245
  48. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research. 2000;45:21–28
  49. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ. 2000;321:483–484
  50. Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. International Journal of Cardiology. 2000;74:S23–S28
  51. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. New England Journal of Medicine. 1998;338:1516–1520(see comments)
  52. Simpson JC, Tsuang MT. Mortality among patients with schizophrenia. Schizophrenia Bulletin. 1996;22:485–499
  53. Sokal J, Messias E, Dickerson FB, Kreyenbuhl J, Brown CH, Goldberg RW, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. Journal of Nervous and Mental Disease. 2004;192:421–427
  54. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin. 2003;29:15–31
  55. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000–2001. Journal of Internal Medicine. 2004;255:494–502
  56. Trilling JS, Froom J. The urgent need to improve hypertension care. Archives of Family Medicine. 2000;9:794–801
  57. Troisi RJ, Cowie CC, Harris MI. Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. JAMA. 2000;284:3157–3159
  58. Winer N, Sowers JR. Epidemiology of diabetes. Journal of Clinical Pharmacology. 2004;44:397–405

☆ Supported by NIMH grant #N01MH90001.

PII: S0920-9964(06)00298-2

doi: 10.1016/j.schres.2006.06.026

Schizophrenia Research
Volume 86, Issue 1 , Pages 15-22 , September 2006

Article Tools